PARD (Poniard Pharmaceuticals) Short-Term Debt: $0.00 Mil (As of Sep. 2011)


What is Poniard Pharmaceuticals Short-Term Debt?

Poniard Pharmaceuticals PARD Short-Term Debt is $0.00 Mil as of Sep. 2011.

Poniard Pharmaceuticals's Short-Term Debt for the quarter that ended in Sep. 2011 was $0.00 Mil.

Poniard Pharmaceuticals's annual Short-Term Debt increased from Dec. 2008 ($7.92 Mil) to Dec. 2009 ($8.60 Mil) but then declined from Dec. 2009 ($8.60 Mil) to Dec. 2010 ($0.00 Mil).

Poniard Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Poniard Pharmaceuticals Short-Term Debt Related Terms

Poniard Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Short-Term Debt Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.91 4.25 7.92 8.60 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.89 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Poniard Pharmaceuticals (PARD) has a Short-Term Debt of $0.00 Mil as of Sep. 2011.
Is Poniard Pharmaceuticals' Short-Term Debt too high?
Poniard Pharmaceuticals' current Short-Term Debt is $0.00 Mil.
How does Poniard Pharmaceuticals' Short-Term Debt compare to OBMP and NSPX?
Poniard Pharmaceuticals' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Poniard Pharmaceuticals's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Short-Term Debt is $0.00 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.